We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

6,600 Open access books available
177,000 International authors and editors
195M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Diabetes Mellitus is a syndrome characterized by hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism associated with absolute or relative deficiencies in insulin secretion and, or insulin action. It is a genetically and clinically heterogeneous group of disorders that share glucose intolerance in common. It is the most common endocrine metabolic disorder world wide affecting people of all races and of different social conditions. It is estimated that approximately 120 million people have diabetes mellitus worldwide and this number is expected to double in the next 25 year. The major part of the increase in the prevalence of diabetes mellitus is expected in the developing countries. In most African populations, it is said that the high prevalence of impaired glucose tolerance (IGT) suggests that public health impact of diabetes could increase in these communities in the future.

Diabetes mellitus is characterized by acute and long term complications and these result in increased morbidity and mortality in diabetics especially in developing countries due to inadequate facilities for treatment and the inability of patients to afford the cost of care. The cardiovascular, renal, retinal and neuropathic long-term complications lead to premature disability and death.

Heart disease has been singled out as a major cause of death in patients with diabetes mellitus, and the risk of atherosclerotic coronary artery disease is substantially increased in patients with both overt diabetes and asymptomatic hyperglycaemia. Several studies have suggested that diabetes may be associated with left ventricular (LV) structural and functional abnormalities in addition to, and independent of atherosclerosis. In the Framingham Cohort, diabetes was associated with higher LV mass in women but not men. High blood pressure (BP), obesity and abnormal lipid profile, which often co-exist with diabetes, tend to be associated with preclinical cardiovascular abnormalities and may contribute to the association of diabetes mellitus with cardiovascular events.

However, there is increasing evidence that diabetics have abnormalities of left ventricular function in the absence of clinical heart disease which is an entity called diabetic cardiomyopathy.

Diastolic left ventricular abnormalities have been disclosed in the past by cardiac catheterisation and abnormal systolic time interval using phonocardiograms, and presently by abnormal left ventricular filling using standard and digitised echocardiography, radionuclide studies and subsequently by Doppler
Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications

106

Echocardiography. Non-invasive methods of assessing left function have confirmed that it is frequently impaired in young asymptomatic diabetics and in those with retinopathy and nephropathy. In diabetes, the left ventricle is not usually dilated or hypertrophied and abnormalities of function are predominantly in diastole, with delayed opening of the mitral valve. Reduced ejection and abnormal systolic function is probably a late event. Possible mechanisms for diabetic cardiomyopathy include excessive myocardial fibrosis, interstitial accumulation of glycoproteins and slow sarcoplasmic calcium reuptake or altered release from a dysfunctional coronary endothelium of mediators such as nitric oxide and endothelin which exert paracrine myocardial effects on diastolic properties.

2. Diastolic dysfunction

2.1 What is diastolic dysfunction?
Diastolic dysfunction can be defined as a condition in which myocardial relaxation and filling are impaired and incomplete. In its most severe form, diastolic dysfunction results in overt symptoms of congestive heart failure. In modest cases, symptoms of dyspnoea and fatigue occur only during stress or activity such as exercise when heart rate and/or end diastolic volume increase. In its mildest forms, diastolic dysfunction can be manifested as slow or delayed pattern of relaxation and filling with little or no elevation in diastolic pressure and no cardiac symptoms. Some factors that have been implicated in left ventricular diastolic dysfunction include: diabetes mellitus, coronary artery disease, hypertensive heart disease, hypertrophic cardiomyopathy, valvular heart disease, cardiac transplantation, cardiac amyloidosis and aging.

2.2 Prevalence of diastolic dysfunction
The prevalence of asymptomatic diastolic dysfunction was estimated at 27% in an epidemiologic study, and was found to increase with age. Results of early studies suggested that as many as 40% of patients with heart failure symptoms have diastolic heart failure. More recent studies showed that of patients hospitalised for heart failure, 35% to 40% present with diastolic heart failure. In the community setting, this number was found to be between 45% and 55%. Two recent studies found the prevalence of diastolic heart failure in women to be 1.5 to 2-fold greater than in men. In a study of 86 normotensive type 2 diabetic patients (43% of whom were women, mean age of 43 years and mean glycosylated haemoglobin of 6.5g/dl), greater than 40% had diastolic dysfunction on Doppler echocardiography. In 1989, Shapiro et al reported a prevalence of 40% amongst a mixed patient population of both type 1 and type 2 diabetics. In a study of one-hundred and twenty Nigerian normotensive type 2 diabetic subjects, only 29% of the diabetic subjects had normal filling function compared to 58% of the normal controls.

2.3 Clinical evidences for diabetic cardiomyopathy
The Framingham study was the first to demonstrate an increased risk of heart failure in patients with diabetes mellitus. When the incidence of heart failure in men and women with diabetes mellitus was compared with that of non diabetic men and women, the
incidence in individuals with diabetes was found to be 2- and 5-fold greater respectively.\textsuperscript{51} Since then, additional trials like Studies of Left Ventricular Dysfunction (SOLVD),\textsuperscript{52} the Heart Outcomes Prevention Evaluation (HOPE) study\textsuperscript{53} and the Cardiovascular Health Study (CHS)\textsuperscript{54} have identified diabetes mellitus as a major risk factor for the development of heart failure. It has been found that close to 30\% of patients with diastolic heart failure have diabetes mellitus.\textsuperscript{55}

Left ventricular diastolic dysfunction is proposed to be the first stage of diabetic cardiomyopathy.\textsuperscript{27,56} In the Strong Heart Study\textsuperscript{57} which enrolled 2,411 Native Americans, individuals with diabetes mellitus had evidence of impaired left ventricular relaxation on Doppler echocardiography. In that study, the association between diabetes mellitus and abnormal left ventricular relaxation was independent of age, blood pressure, LV mass and LV systolic function. The abnormalities were more severe in the diabetes-hypertension group, showing the additive deleterious effects on active LV relaxation when both of these conditions are present. Poirier et al\textsuperscript{58} reported that patients with well-controlled diabetes and without overt coronary artery disease, hypertension or heart failure have lower levels of exercise performance on maximal treadmill testing than do age-matched controls. This exercise limitation correlated with the severity of diastolic dysfunction as assessed by Doppler echocardiography.

Several workers have studied the correlation between left ventricular diastolic function and factors such as duration of diabetes mellitus, glycaemic control, microangiopathy, microalbuminuria and systemic hypertension. In the study of thirty patients with type 2 diabetes mellitus, Fiorini et al\textsuperscript{59} found no correlation between duration of diabetes mellitus and diastolic dysfunction. Also, in the study of one hundred and twenty-five (125) type I diabetics, some workers\textsuperscript{60} found no correlation between duration of diabetes and diastolic dysfunction. Also, other workers\textsuperscript{61} in the study of twelve (12) type I diabetic patients found that diastolic abnormalities are not related to the duration of the disease. However, Bertoni et al\textsuperscript{62} in the study of twenty-six (26) young subjects with type 1 diabetes mellitus of at least three years duration, found that there is a correlation between diastolic dysfunction and duration of diabetes mellitus.

In the Veterans Affairs Co-operative Study in type 2 Diabetes Mellitus (VACSDM)\textsuperscript{63}, it was found that two years of intensive glycaemic control did not affect the left ventricular systolic or diastolic functions in patients with type 2 diabetes. Also in the study of twenty normotensive patients with a new diagnosis of type 2 diabetes mellitus, some workers\textsuperscript{64} found that diastolic function was impaired at diagnosis and was not affected by an improvement in the glycaemic control. However, Felicio et al\textsuperscript{65} in the study of fifty-six hypertensive patients with type 2 diabetes mellitus concluded that even though there was no correlation between diastolic dysfunction and glycaemic control, improvement in glycaemic control may contribute to LVH regression in hypertensive patients with type 2 diabetes mellitus.

Cecchi et al\textsuperscript{66} in the study of forty recently diagnosed type 1 diabetics (with and without microangiopathy) showed that slight preclinical diastolic dysfunction is present in young recently diagnosed type 1 diabetic without microangiopathy. But it was found that more severe dysfunction is present when there is also microangiopathy. Some other workers\textsuperscript{56} confirmed this in the study of 26 young subjects with type 1 diabetes mellitus. They showed that there is an often sub-clinical cardiac abnormality in young diabetics resulting in impairment of diastolic function that is correlate with the presence of clinical complications such as nephropathy and retinopathy.
Liu et al in the strong Heart study\textsuperscript{57} showed that albuminuria is independently associated with LV systolic and diastolic dysfunction in type 2 diabetics. Some other workers\textsuperscript{67} in the study of forty-two patients with mild-to-moderate essential hypertension and type 2 diabetes mellitus found that an elevated urinary albumin excretion is associated with an increased left ventricular mass index. They also found that urinary albumin excretion is associated with a higher prevalence of concentric left ventricular hypertrophy pattern, a depressed midwall systolic performance and a markedly impaired diastolic function. Also Mori et al\textsuperscript{68} in the study of twenty-one type 2 diabetes found that left ventricular diastolic function may be related to both hypertension and proteinuria. In the study of ten age-controlled type 2 diabetes, it was found by Poirier et al\textsuperscript{69} that left ventricular diastolic dysfunction and cardiac autonomic neuropathy are associated in patients with otherwise uncomplicated well-controlled type 2 diabetes mellitus.

3. Pathogenesis of diabetic cardiomyopathy

The pathogenesis of diabetic cardiomyopathy has been illustrated in figure 1. The morphologic changes in the diabetic heart include myocyte hypertrophy, increased matrix collagen, interstitial fibrosis, and intra-myocardial microangiopathy.\textsuperscript{70} These changes are probably consequences of altered myocardial glucose and fatty acid metabolism due to diabetes.\textsuperscript{50} Chronic hyperglycaemia leads to nonenzymatic glycation of vascular and membrane proteins, producing advanced glycation end products (AGEs) and reactive oxygen species.\textsuperscript{67} Once AGEs develop in the arterial wall and myocardium, they form stable and irreversible crosslinks with adjacent collagen polymers thereby decreasing the compliance of the blood vessels and myocardium.\textsuperscript{67} The AGEs and reactive oxygen species will also affect ion channel, calcium homeostasis, and mitochondrial function, as well as initiating apoptosis, leading to contractile dysfunction-glucotoxicity.\textsuperscript{67}

Diabetes is also characterised by an increased turnover of free fatty acids. The increased free fatty acid turnover leads to increased myocardial oxygen consumption and enhances the intracellular accumulation of intermediates, leading to deleterious effects-lipotoxicity.\textsuperscript{67} These effects include interference with ATP-dependent ion pumps and mobilisation of intracellular calcium, thereby creating calcium overload and relaxation abnormalities. Impaired glucose oxidation also leads to lactic acid accumulation that further promotes the degradation of free fatty acids.\textsuperscript{68}

Other myocardial changes in diabetes include impairment of beta-receptor signal transduction and induction of fetal gene pattern.\textsuperscript{70,71} The fetal gene pattern leads to upregulation of beta-myosin heavy chain and downregulation of alpha-myosin heavy chain gene which is the fast -contracting isoform of myosin heavy chain that contains much greater ATPase activity than does beta-myosin heavy chain.\textsuperscript{72} In addition, there is downregulation of the SERCA gene,\textsuperscript{73} leading to impaired myocardial calcium handling.\textsuperscript{74} These changes in gene expression are closely associated with abnormalities in diastolic function.\textsuperscript{75}

To support the theory that abnormalities in high-energy phosphate metabolism may cause diastolic dysfunction in diabetes, magnetic resonance imaging study demonstrated LV diastolic dysfunction in 12 asymptomatic, normotensive, nonobese patients with well-controlled diabetes when compared with control subjects matched for age, sex, body mass index, and blood pressure.\textsuperscript{76} These findings were associated with a significantly lower ratio of myocardial phosphocreatine to ATP in-patients with diabetes compared with controls.\textsuperscript{91}
Results of previous studies in non-diabetic individuals with LV hypertrophy suggested that the lower phosphocreatine content and the switch in substrate preference from glucose to fatty acids may lead to lower levels of ATP in the sarcomeres that cannot be overcome by increased mitochondrial ATP production\textsuperscript{27}. Lower cytosolic ATP concentrations are associated with impaired calcium sequestration by the sarcoplasmic reticulum and impaired relaxation of cardiomyocytes\textsuperscript{26}.

Increased free FA (FFA) activates PPAR- signaling, leading to the increased transcription of many genes involved in FA oxidation. Increased FA oxidation leads to the generation of ROS at the level of the electron transport chain. ROS, which also can be generated by extramitochondrial mechanisms such as NADPH oxidase, plays a critical role in several pathways involved in the pathogenesis of diabetic cardiomyopathy, including lipotoxicity, cell death, and tissue damage, as well as mitochondrial uncoupling and reduced cardiac efficiency. TG= triglycerides; GLUTs= glucose transporters; PDK4=pyruvate dehydrogenase kinase 4; MCD=malonyl-coenzyme A decarboxylase; MCoA= malonyl-coenzyme A; ACoA=acetyl-coenzyme A; ACC= acetyl coenzyme A carboxylase; CPT1= carnitine palmitoyl-transferase 1; PDH= pyruvate dehydrogenase; CE= cardiac efficiency; PKC= protein kinase C; and AGE= glycation end products
4. Diagnosing diastolic dysfunction

Differentiating between diastolic and systolic dysfunction on clinical grounds is very difficult, although clues may be given by the patient’s past history, clinical presentation, physical examination, radiographic and electrocardiographic findings. Exertional dyspnoea because of pulmonary congestion is frequently an early event in diastolic dysfunction.

More commonly, estimates of left ventricular size and systolic function are needed in order to determine whether congestive heart failure is caused by systolic or diastolic dysfunction. These measurements can be made using echocardiography, radionuclide ventriculography, or contrast ventriculography.

Precisely, the definite diagnosis of diastolic dysfunction or failure depends on the observation of an appropriate upward shift of the (end-) diastolic pressure – volume relation. Therefore, objective evidence of ventricular diastolic dysfunction requires cardiac catheterisation with volume determinations using frame-by-frame analysis of left ventricular contrast angiograms or impedance measurements and high-fidelity measurements of ventricular pressure with a micromanometer. However, due to the invasive nature, high cost, and limited availability of haemodynamic studies, this remains impractical for widespread use or for serial follow-up examinations thereby leaving echocardiography as the gold standard.

4.1 Echocardiography

Doppler echocardiography has become the most widely used and accepted method for the diagnosis and follow-up of patients with diastolic dysfunction. Its reliability, reproducibility, ease of performance, and advances in applications over the past decade makes it the ideal tool for the assessment of “diastology.” The basis of the Doppler echocardiographic assessment of diastolic function relies on a careful, integrated approach. The mainstay of this approach involves the recording of flow velocities across the mitral valve and within the pulmonary veins to assess filling patterns and estimate left ventricular filling pressure indirectly.

Mitrail flow velocities are obtained by pulse-wave Doppler echocardiography placing the sample volume located between the tips of the mitral valve leaflet during ventricular diastole (as shown in figure 2). The peak velocity of early rapid filling (E), peak velocity of late filling caused by atrial contraction (A), E/A ratio, the interval from the peak of E velocity to its extrapolation to baseline or the deceleration time (DT) and the interval from aortic valve closure to mitral valve opening or isovolumic relaxation time (IVRT) is measured.

Pulmonary venous flow is measured using pulse-wave Doppler echocardiography with sample volume located 1-2cm into a pulmonary vein, proximal to its insertion into the left atrium (as shown in figure 3). The systolic peak velocity which is biphasic in 30% of cases (S), diastolic peak velocity (D), the S/D ratio, atrial systolic reversal velocity (A) are measured. Based on Doppler echocardiographic studies, diastolic filling is classified into: normal, impaired relaxation or mild diastolic dysfunction, moderate diastolic dysfunction or pseudonormal filling and severe diastolic dysfunction or restrictive filling.

4.2 Normal filling

The determinants of LV filling, ventricular relaxation and effective chamber compliance change with increasing age. This leads to different diastolic filling patterns for different
In normal young individuals aged (20s – 30s), LV relaxation is rapid, the majority of filling (85-95%) occurring in early diastole and only a small proportion (5-15%) occurring with atrial contraction. This results in mitral inflow parameters of E/A between 1-2 (mean 1.8), and relatively short deceleration time (mean 182msec) and isovolumetric relaxation time (mean 71msec). Pulmonary venous inflow usually shows a slight systolic predominance (S>D) with a mean pulmonary ‘A’ of 0.19m/sec.

RV = Right Ventricle
LV = Left Ventricle
RA = Right Atrium
LA = Left Atrium
SV = Sample Volume
AMVL = Anterior Mitral Valve Leaflet
PMVL = Posterior Mitral Valve Leaflet
E = Mitral E wave
A = Mitral A wave

Fig. 2. Echocardiogram showing measurement of Transmitral Flow Velocity Profile ('E' and 'A' Waves)

With aging, the rate of LV relaxation decreases with slower and less filling in early diastole and an increased contribution to LV filling by atrial contraction. This leads to a prolongation
of the IVRT and DT, a reduction in E velocity, and an increase in A velocity with a subsequent reduction in E/A ratio. Individuals >65 years have the following average parameters: E/A ratio of less than 1, a mean DT greater than 214msec, and IVRT greater than 094msec. As pulmonary D parallels the pulmonary S velocity, the pulmonary venous flow now shows diastolic predominance (D>S). As well, the A increases slightly, but does not exceed the upper limit of normal (0.35m/sec).

**Fig. 3. Echocardiogram showing measurement of Pulmonary Flow Velocity Profile**

**4.3 Mild diastolic dysfunction**
This represents the earliest stage of diastolic dysfunction. There is impaired LV relaxation with initially normal LV filling pressures, leading to decreased early filling and increased filling with atrial contraction. Mitral inflow patterns show an E/A less than 1 which is
abnormal for the age. The IVRT is prolonged (>100 msec), with prolongation of the DT (>200 msec). Pulmonary venous inflow normally remains normal with systolic predominance ($S>D$), and with pulmonary ‘$A’$<0.35 m/sec.\textsuperscript{90}

### 4.4 Moderate diastolic dysfunction
As diastolic dysfunction progresses, LV relaxation becomes further impaired and LV stiffness increases.\textsuperscript{90} In an attempt to maintain LV filling and cardiac output, the filling pressure, specifically left atrial (LA) pressure becomes elevated. This increased transmural pressure gradient leads to increased early filling with the E/A ratio ‘normalizing’ to a value >1, with prolongation of IVRT and DT to high values. This mitral pattern is similar to the pattern in normal individuals, leading to the term ‘pseudonormal’. The differentiation from normal is done on the basis of an abnormal response to the valsala manoeuvre or as abnormal pulmonary venous flow pattern.\textsuperscript{90}

### 4.5 Severe diastolic dysfunction
As diastolic dysfunction progresses further, LV relaxation continues to be impaired, however, it is marked by rising LV filling pressures and a markedly reduced LV compliance. This mimics the physiology of restrictive cardiomyopathy.\textsuperscript{87} The increased LA pressure causes an early mitral valve opening and rapid early filling (increased E velocity). As early rapid filling occur into a noncompliant LV, there is rapid equalization of LV and LA pressured leading to a shortened DT.\textsuperscript{90} Atrial contraction into a noncompliant LV with high diastolic pressure leads to a reduced A velocity. Therefore, the E/A ratio is >2, and occasionally >4 to 5. Pulmonary venous inflow shows a marked blunting of systolic inflow ($PS<<PD$) corresponding to the markedly elevated LA pressure and reduced LA compliance.\textsuperscript{87}

### 5. Conclusion
Abnormal left ventricular relaxation seen in diabetics, independent of other factors has been shown to contribute to the incidence of congestive heart failure despite normal left ventricular ejection fraction.\textsuperscript{55} It is therefore another cause of clinical cardiovascular morbidity. In addition, reduced or increased mitral E/A ratio has been shown to be independently associated with increased all cause mortality as well as cardiovascular mortality.\textsuperscript{81} It is therefore necessary to detect early, diabetic patients with left ventricular diastolic dysfunction and commence treatment modalities such as use of selective β – blockers and ACE inhibitor.\textsuperscript{131} However, there have not been prospective intervention studies to determine the reversibility and effectiveness of such treatments.

### 6. References
Bennett PH. Diabetes – Definition and Pathogenesis. In: Kahn CR, Weir GC. (Eds). Joslin’s Diabetes Mellitus. Thirteenth edition. Lea and Febiger (Publishers), Philadelphia. 1994: 193-200.

National Diabetes Data Group. Classification and diagnosis of Diabetes Mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
Famuyiwa OO. Important considerations in the care of diabetic patients in Nigeria. International diabetes Digest 1993; 4: 48-51.

King H, Rewers M.WHO Ad Hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes and impaired glucose tolerance in adults. Diabetes care 1993; 16:157-177.

King H. Diabetes Mellitus: a growing international health care problem. International Diabetes Monitor 1997; 9:1-6.

King H, Rewers M.WHO Ad Hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes and impaired glucose tolerance in adults. Diabetes care 1993; 16:157-177.

World Health Organisation. Prevention of Diabetes Mellitus: report of a WHO study group. WHO Technical report series 1994; 844.

Rubler S, Sajadi RM, Araoye MA, Holford FD. Non invasive estimation of myocardial performance in patients with diabetes. Effect of alcohol administration. Diabetes 1978; 27: 127-34.

D’Elia JA, Weinrauch LA, Healy RW, Libertino JA, Bradley R, Leland OS. Myocardial dysfunction without coronary artery disease in diabetic renal failure. Am J cardiol 1979; 43: 193-19.

Shapiro LM, Howat AP, Calter MM. Left ventricular function in diabetes mellitus. 1. Methodology and prevalence and spectrum of abnormalities. Br Heart J 1981; 45: 122-128.

Shapiro LM, Leatherdale BA, Mackinnon J, Fletcher RF. Left Ventricular Function in diabetes mellitus. II. Relation between clinical features and left ventricular function. Br Heart J 1981; 45: 129-132.

Sanderson JE, Brown DJ, Rivellese A, Kohner E. Diabetic Cardiomyopathy? An echocardiographic study of young diabetes. Br Med J 1978; i: 404-7.

Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993, 88; 1444-1455.

Ahmed SS, Jaferi GA, Narany RM, et al. Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J.1975; 89:153-158.

Grossman E, Shemesh J, Shamiss A, et al. Left Ventricular mass in diabetes- hypertension. Arch Intern Med. 1992; 152:1001-1004.

Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977; 60: 885-899.

Shapiro LM, Howat AP, Calter MM. Left ventricular function in diabetes mellitus. 1. Methodology and prevalence and spectrum of abnormalities. Br Heart J 1981; 45: 122-128.

Shapiro LM, Leatherdale BA, Mackinnon J, Fletcher RF. Left Ventricular Function in diabetes mellitus. II. Relation between clinical features and left ventricular function. Br Heart J 1981; 45: 129-132.

Sanderson JE, Brown DJ, Rivellese A, Kohner E. Diabetic cardiomyopathy? An echocardiographic study of young diabetics. Br. Med J 1978; i: 404-7.
Danielsen R, Nordrehaug JE, Lien E, Vik-Mo H. Subclinical left ventricular abnormalities in young subjects with long-term type 1 diabetes mellitus detected by digitized M-mode echocardiography. Am J Cardiol 1987; 60: 143-146.

Takenaka K, Sakamoto T, Amano K, Oku J, Murakami T, Toda I, Kawakubo K, Sugimoto T. Left Ventricular filling determined by Doppler echocardiography in diabetes mellitus. Am J Cardiol 1988; 61: 1140-1143.

Zarich SW, Arbuckle BE, Cohen LR, Roberts H, Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by Pulsed Doppler echocardiography. JACC 1988; 12: 114-130.

Rynkiewicz A, Semetkowska-Jurkiewicz E, Wyrzkowski B. Systolic time. Intervals in young diabetics. Br Heart J 1980; 44: 280-3.

Ahmed SS, Jaffer GA, Narang RM, Regan TJ; Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J 1975; 89: 153-8.

Shapiro LM, Leatherdale BA, Loyne ME, Fletcher RF, Mackinnon J. Prospective study of heart disease in untreated maturity onset diabetes. Br Heart J 1980; 44: 342-8.

Seneviratne BIB. Diabetic cardiomyopathy: the preclinical phase. Br Med J 1977; i: 1444-6.

Sanderson JE, Brown DJ, Rivellese A, Koerner E. Diabetic Cardiomyopathy; An echocardiographic study of young diabetics. Br Med J 1978; i: 404-7.

Shapiro LM, Leatherdale BA, Mackinnon J, Fletcher RF. Left ventricular function in diabetes mellitus. II: Relation between clinical features and left ventricular function. Br Heart J 1981; 45: 129-32.

Hoeven KH, Factor SM. A comparison of the pathological Spectrum of hypertensive, diabetic and hypertensive-diabetic heart disease. Circulation 1990; 82: 848-55.

Goetzche O. Myocardial cell dysfunction in diabetes mellitus. A review of clinical and experimental studies. Diabetes 1986; 35: 1158-62.

Paulus WJ. Paracrine coronary endothelial modulation of diastolic left ventricular function in man: implications for diastolic heart failure. J Cardiac Failure 1996; 2: S155-164.

Shah AM. Paracrine modulation of heart cell function by endothelial cells. Cardiovasc Res 1996; 31: 847-67.

Gaasch WH, Schick EC, Zile MR. Management of left ventricular diastolic dysfunction. In: Smith TW (ed). Cardiovascular therapeutics. A companion to Braunwald’s Heart Disease, Philadelphia: W.B. Sanders company, 1996; 237-242.

Lorell BH. Significance of diastolic dysfunction of the heart. Am Rev Med 1991; 42: 411-436.

Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 1992; 117: 502-510.

Zile MR. Diastolic dysfunction and heart failure in hypertrophied hearts. CHF 1998; 4: 32-42.

Catherine Paillolle, Micheal Dahan, Frederic Paycha et al. Am J Cardiol 1989; 64: 1010-1016.

Zile MR, Brusaert DL. New concepts in diastolic dysfunction and diastolic heart failure. I. Diagnosis, prognosis and measurements of diastolic function. Circulation 2002; 105: 1387-1393.

Redfield MM, Jacobsen SJ, Burnett JC Jr et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.

Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiological perspective’s Am Coll Cardiol. 1995; 26: 1565-1574.
Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol. 2003;41:1510-1518.

EF, Rocco TA, Lindenmuth NW, et al. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med. 2000;109:605-613.

Pernenki R, Vinson JM, Shah AS, et al. Course and prognosis in patients Greater than 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol. 1997;79:216-219.

Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in Subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in population based cohort. J Am Coll Cardiol. 1999;33:1948-1955.

Senni M, Triboulloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted county, Minnesota, in 1991. Circulation. 1998;98:2282-2289.

Kitzman DW, Gardin JM, Gottdiener JS, et al., for Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients greater than 65 years of age. Am J Cardiol. 2001;87:413-419.

Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol. 1997;30:1417-1419.

Ojji D, Parsonage W, Dooris M, Adebiyi A, Oladapo O, Adeleye J, Aje A, Ogah O, Adebayo A, Falase A, Atherton J. J Natl Med Assoc. 2008 Sep;100(9):1066-72

Jonathan P P, Liviu K, Mihai G, Robert O B. New Insights into Diastolic Heart Failure: Role of Diabetes Mellitus. Am J Med. 2004;116 (5A): 645-755.

Kannel WB, Hjortland M, Castelli W P. Role of diabetes in congestive Heart failure: the Framingham study. Am J Cardiol. 1974; 34:29-34.

Parker AB, Yusuf S, Naylor CD. The relevance of sub-group-specific treatment effects: the studies of Left Ventricular Dysfunction (SOLVD) revisited. Am Heart J. 2002; 144:941-947.

Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE Study. Circulation. 2003;107:1284-1290.

Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of Congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000; 35:1628-1637.

O’Connor CM, Gattis WA, Shaw L, et al. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol. 2000;86:863-867.

Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? : an echocardiographic study of young type 1 diabetic patients. Diabetes Care. 1994;17:633-639.

Liu JE, V,Robbins DC,Palmieri V,Bella JN,Roman MJ,et al.The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study.J Am Coll Cardiol.2003; 41:2022-2028.

Poirier P, Bogaty P, Philippon F, Garneau C, Fortin C et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes:importance of manoeuvres in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 2001;24:5-10.
Fiorini G, Scotti LA, Parmigiani ML, Ferrari M, Pezzoli P et al. An echocardiographic study of left ventricular diastolic in patients with type 2 diabetes mellitus. Cardiol 1995 Jan; 25(1):17-25.

Illan F, Valdes-Chavarri M, Tebar J, Garcia A, Pascual H et al. Anatomic and functional cardiac abnormalities. Clin Invest. 1992 May; 70(5):403-10.

Chiarella F, Viviani GL, Belloti P, Briata P, Domenicucci S et al. Left Ventricular Diastolic Function in Type 1 Diabetes Mellitus. G Ital Cardiol 1986 Jul; 16(7):544.

Bertoni PD, Morandi G, Di Michele R, Canziani R et al. Altered diastolic function of the left ventricle in juvenile diabetes. G Ital Cardiol 1984 Nov; 14(11):839-46.

Pitale SU, Abraira C, Emanuele NV, McCarren M, Hendreson WG et al. Two years intensive glycaemic control and left Ventricular function in the Veterans Affairs Co-operative study in type 2 diabetes mellitus. Diabetes Care 2000 Sep; 23(9):1316-20.

Gough SC, Smyllie J, Barker M, Berkin KE, Rice PJ et al. Diastolic dysfunction is not related to changes in glycaemic control over 6 months in type 2 diabetes mellitus. A cross sectional study. Acta Diabetol 1995 Jun; 32(2):110-5.

Felicio JS, Ferreira SR, Plavnik FL, Moises V, Kohlmann O et al. Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. Hypertens 2000 Nov; 3(11):1149-54.

Cecchi E, Pomari F, Brusasco G, Angelino P, Blatto A, et al. Preclinical left ventricular diastolic dysfunction in insulin dependent diabetes. G Ital Cardiol 1994 Jul; 24(7):839-44.

Poirier P, Garneau C, Bogaty P, Nadeau A, Marois L et al. Preclinical diabetic cardiomyopathy: relation of Cardiovascular diastolic dysfunction to cardiac autonomic neuropathy in men with uncomplicated well-controlled type 2 diabetes. Metabolism 2003 Aug; 52(8):1056-617.

Hardin N. The myocardial and vascular pathology of diabetic Cardiomyopathy. Coron. Artery Dis. 1996; 7:99-108.

Young ME, McNulty P, Taegtmeyer H. Adaptation and mal-adaptation of the heart in diabetes. II. Potential mechanisms. Circulation. 2002; 105:1861-1870

Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic Cardiomyopathy. Mol Cell Biol Biochem. 1998; 180:53-57.

Rupp H, Elimban V, Dalla NS. Modification of myosin isoenzymes and SR Ca(2+)-pump ATPase of the diabetic rat heart by lipid-lowering interventions. Mol Cell Biochem. 1994; 132:69-80.

Bristow MR. Why does the myocardium fail?:insights from basic Science. Lancet. 1998; 352:58-514.

Depre C, Young ME, Ying J, et al. Streptozotocin-induced changes in Cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cardiol. 2000; 32:985-996.

Golfman L, Dixon IM, Takeda N, et al. Differential changes in cardiac Myofibrillar and sarcoplasmic reticular gene expression in alloxan-induced diabetes. Mol cell Biochem. 1999; 200:15-25.

Flasheim CE, Grupp IL, Matlib MA. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol. 1996; 271:H192-H202.

Bristow MR. Etomoxir: A new approach to treatment of chronic heart Failure. Lancet. 2000; 356:1621-1622.
Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. Am Coll Cardiol. 2003; 42:328-335.

Bonito A. Doppler assessment of left ventricular systolic and diastolic function. In: Bonito A (ed). Echocardiography. The Normal Examination and Echocardiographic Measurements, Brisbane: Fergies, 2000;189-227

European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1999;19:990-1003.

Zile MR. Diastolic heart failure: Diagnosis, mechanisms, and Treatment. Cardiology Rounds, 1999; 3(3): 1-6.

Mirsky I. Assessment of diastolic function: suggested methods and future considerations. Circulation 1984; 69:836-41.

Shah PM, Pai RM. Diastolic heart failure. Curr.Probl. Cardiol. 1992; 17:783-86.

Clarkson P, Wheeldon NM, Macdonald TM. Left ventricular diastolic dysfunction. QJM 1994; 87:143-148

Nishimura RA, Tajik AJ: Evaluation of diastolic filling of the left Ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta stone. J Am Coll Cardiol 1997; 30:8-18.

Oh JL, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The non-invasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc echocard 1997; 10:246-270.

Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity Patterns to left ventricular diastolic function: new insights from a combined haemodynamic and Doppler echocardiography. J Am Coll Cardiol 1988;12:426-440.

Rakowski H, Appleton CP et al. Canadian Consensus Recommendation for the Measurement and Reporting of Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiog. 1996; 9:736-60.

Vasan RS, Levy D. Defining diastolic heart failure. A call for standardized diagnostic criteria. Circulation 2000;101:2118-2121

Packer M. Abnormalities of diastolic function as potential cause of exercise intolerance in chronic heart failure. Circulation 1990;81(111):78-86

Gilbert J, Glantz S. Determinants of left-ventricular filling and of the diastolic pressure-volume relation. Circ Res 1989; 64: 827-852

Bella JN, Palmieri V, Roman MJ. Prognostic significance of abnormal peak early to late diastolic filling ratio in middle-aged to elderly American Indians: The Strong Heart Study (abstr).JACC 2000;35:293A.
Type 2 diabetes mellitus affects nearly 120 million persons worldwide and according to the World Health Organization this number is expected to double by the year 2030. Owing to a rapidly increasing disease prevalence, the medical, social and economic burdens associated with the microvascular and macrovascular complications of type 2 diabetes are likely to increase dramatically in the coming decades. In this volume, leading contributors to the field review the pathogenesis, treatment and management of type 2 diabetes and its complications. They provide invaluable insight and share their discoveries about potentially important new techniques for the diagnosis, treatment and prevention of diabetic complications.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Dike Bevis Ojji (2011). Diabetic Cardiomyopathy, Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications, Prof. Mark Zimering (Ed.), ISBN: 978-953-307-597-6, InTech, Available from: http://www.intechopen.com/books/recent-advances-in-the-pathogenesis-prevention-and-management-of-type-2-diabetes-and-its-complications/diabetic-cardiomyopathy
